NCT01465659View on ClinicalTrials.gov

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 12, 2011

Primary Completion Date

July 30, 2018

Study Completion Date

January 27, 2021

Conditions
Pancreatic Alpha Cell CarcinomaPancreatic Beta Islet Cell CarcinomaPancreatic Delta Cell CarcinomaPancreatic G-cell CarcinomaRecurrent Islet Cell Carcinoma
Interventions
DRUG

temozolomide

Given PO

DRUG

pazopanib hydrochloride

Given PO

Trial Locations (5)

37232

Vanderbilt University, Nashville

48109

University of Michigan, Ann Arbor

60611

Northwestern University, Chicago

98109

University of Washington Seattle Cancer Care Alliance, Seattle

19111-2497

Fox Chase Cancer Center, Philadelphia

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

Robert H. Lurie Cancer Center

OTHER

collaborator

National Comprehensive Cancer Network

NETWORK

collaborator

GlaxoSmithKline

INDUSTRY

lead

Northwestern University

OTHER

NCT01465659 - Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter